NASDAQ:FMTX
Delisted
Forma Therapeutics Holdings Inc. Stock News
$20.01
+0 (+0%)
At Close: Jan 27, 2023
Forma Therapeutics shares jump 50%; here is why
10:38pm, Friday, 02'nd Sep 2022
Forma Therapeutics Holdings Inc (NASDAQ: FMTX) shares are up 50% after announcing a definitive agreement with Novo Nordisk.
Why Forma Therapeutics Holdings Stock Is On Fire Today
02:36pm, Thursday, 01'st Sep 2022
The rare blood disorder specialist is the latest biotech buyout target.
Novo Nordisk Jumps Into Sickle Cell Fray With $1.1 Billion Forma Therapeutics Buyout
12:14pm, Thursday, 01'st Sep 2022
Novo Nordisk said Thursday it will spend $1.1 billion to acquire Forma in a deal that sent biotech stock Forma flying. The post Novo Nordisk Jumps Into Sickle Cell Fray With $1.1 Billion Forma Therape
Why Novo Nordisk (NVO) Is Buying Forma Therapeutics (FMTX) For $1.1 Billion
09:20am, Thursday, 01'st Sep 2022
Novo Nordisk (NYSE: NVO) is buying Forma Therapeutics, Holdings Inc (Nasdaq: FMTX) for $1.1 billion. This is why.
Novo Nordisk to acquire Forma Therapeutics in $1.1. billion deal
08:19am, Thursday, 01'st Sep 2022
Danish drugmaker Novo Nordisk will acquire Forma Therapeutics in a deal valued at $1.1 billion to expand its rare blood disorders portfolio, the companies said on Thursday.
Forma Therapeutics to be acquired by Novo Nordisk in a cash deal valued at $1.1 billion
08:18am, Thursday, 01'st Sep 2022
Forma Therapeutics Holdings Inc. FMTX, +1.67% announced Thursday and agreement to be acquired by Denmark-based Novo Nordisk NVO, +0.06% NOVO.B, -0.59% in a deal with an equity value of $1.1 billion. F
Forma Therapeutics: Rare Disease Play
10:32am, Wednesday, 31'st Aug 2022
72% technical buy signal. 15 new highs and up 59.18% in the last month.
Forma Therapeutics Holdings Inc. (FMTX) CEO Frank Lee on Q2 2022 Results - Earnings Call Transcript
10:21am, Friday, 05'th Aug 2022
Forma Therapeutics Holdings Inc. (NASDAQ:FMTX ) Q2 2022 Earnings Conference Call August 5, 2022 8:00 AM ET Company Participants Adam Bero - Investor Relations Frank Lee - President and Chief Executive
Forma Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 5, 2022
07:05am, Friday, 29'th Jul 2022
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 5, 2022
Can Forma Therapeutics Holdings, Inc. (FMTX) Climb 536% to Reach the Level Wall Street Analysts Expect?
11:35am, Wednesday, 22'nd Jun 2022
The average of price targets set by Wall Street analysts indicates a potential upside of 536% in Forma Therapeutics Holdings, Inc. (FMTX). While the effectiveness of this highly sought-after metric is
Bears are Losing Control Over Forma Therapeutics Holdings, Inc. (FMTX), Here's Why It's a 'Buy' Now
11:34am, Wednesday, 15'th Jun 2022
Forma Therapeutics Holdings, Inc. (FMTX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, str
Forma Therapeutics to Present at the Jefferies Healthcare Conference
07:05am, Friday, 03'rd Jun 2022
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Present at the Jefferies Healthcare Conference
Forma Therapeutics Holdings Inc. (FMTX) CEO Frank Lee on Q1 2022 Results - Earnings Call Transcript
12:30pm, Friday, 06'th May 2022
Forma Therapeutics Holdings Inc. (NASDAQ:FMTX ) Q1 2022 Earnings Conference Call May 6, 2022 8:00 AM ET Company Participants Frank Lee – President and Chief Executive Officer Mario Corso – Senior
Forma Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 6, 2022
07:05am, Friday, 29'th Apr 2022
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 6, 2022
Forma Therapeutics Holdings' (FMTX) CEO Frank Lee on Q4 2021 Results - Earnings Call Transcript
01:09pm, Tuesday, 01'st Mar 2022
Forma Therapeutics Holdings' (FMTX) CEO Frank Lee on Q4 2021 Results - Earnings Call Transcript
